These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25186922)

  • 1. Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study –.
    Ogawa H; Matsui K; Saito Y; Sugiyama S; Jinnouchi H; Sugawara M; Masuda I; Mori H; Waki M; Yoshiyama M; Watada H
    Circ J; 2014; 78(10):2512-5. PubMed ID: 25186922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
    Kurabayashi M; Yamazaki T;
    J Atheroscler Thromb; 2008 Dec; 15(6):314-23. PubMed ID: 19060425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.
    Park JS; Kim YJ; Choi JY; Kim YN; Hong TJ; Kim DS; Kim KY; Jeong MH; Chae JK; Oh SK; Seong IW
    Korean J Intern Med; 2010 Mar; 25(1):27-35. PubMed ID: 20195400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.
    Mori Y; Kuriyama G; Tanaka T; Tajima N
    Endocrine; 2009 Dec; 36(3):412-8. PubMed ID: 19834827
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study.
    Simsek S; Schalkwijk CG; Wolffenbuttel BH
    Diabet Med; 2012 May; 29(5):628-31. PubMed ID: 22151023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
    Asztalos BF; Le Maulf F; Dallal GE; Stein E; Jones PH; Horvath KV; McTaggart F; Schaefer EJ
    Am J Cardiol; 2007 Mar; 99(5):681-5. PubMed ID: 17317371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
    Koshel'skaia OA; Vinnitskaia IV; Konko TIu; Kravchenko ES; Suslova TE; Karpov RS
    Kardiologiia; 2015; 55(3):67-74. PubMed ID: 26320293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
    Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
    Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
    Leiter LA; Rosenson RS; Stein E; Reckless JP; Schulte KL; Schleman M; Miller P; Palmer M; Sosef F;
    Atherosclerosis; 2007 Oct; 194(2):e154-64. PubMed ID: 17229426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
    Ballantyne CM; Raichlen JS; Cain VA
    J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
    Insull W; Ghali JK; Hassman DR; Y As JW; Gandhi SK; Miller E;
    Mayo Clin Proc; 2007 May; 82(5):543-50. PubMed ID: 17493418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
    Thongtang N; Ai M; Otokozawa S; Himbergen TV; Asztalos BF; Nakajima K; Stein E; Jones PH; Schaefer EJ
    Am J Cardiol; 2011 Feb; 107(3):387-92. PubMed ID: 21257003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers.
    van Himbergen TM; Matthan NR; Resteghini NA; Otokozawa S; Ai M; Stein EA; Jones PH; Schaefer EJ
    J Lipid Res; 2009 Apr; 50(4):730-9. PubMed ID: 19043140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins.
    Bergheanu SC; Reijmers T; Zwinderman AH; Bobeldijk I; Ramaker R; Liem AH; van der Greef J; Hankemeier T; Jukema JW
    Curr Med Res Opin; 2008 Sep; 24(9):2477-87. PubMed ID: 18655752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy.
    Juszczyk MA; Seip RL; Thompson PD
    Prev Cardiol; 2005; 8(4):197-9. PubMed ID: 16230873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
    Schneck DW; Knopp RH; Ballantyne CM; McPherson R; Chitra RR; Simonson SG
    Am J Cardiol; 2003 Jan; 91(1):33-41. PubMed ID: 12505568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
    Hong YJ; Jeong MH; Hachinohe D; Ahmed K; Choi YH; Cho SH; Hwang SH; Ko JS; Lee MG; Park KH; Sim DS; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    Circ J; 2011; 75(2):398-406. PubMed ID: 21157106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.
    Rawlings R; Nohria A; Liu PY; Donnelly J; Creager MA; Ganz P; Selwyn A; Liao JK
    Am J Cardiol; 2009 Feb; 103(4):437-41. PubMed ID: 19195498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.